Publications by authors named "Keith T Demarest"

45Publications

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.

Bioorg Med Chem Lett 2013 Dec 9;23(24):6773-6. Epub 2013 Oct 9.

Cardiovascular and Metabolism Research, Janssen Research and Development, LLC, Welsh & McKean Roads, Spring House, PA 19477, USA. Electronic address:

View Article and Find Full Text PDF
December 2013

Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.

PLoS One 2012 3;7(8):e42134. Epub 2012 Aug 3.

Cardiovascular and Metabolism Therapeutic Area, Janssen Pharmaceutical Companies of Johnson and Johnson, Spring House, Pennsylvania, United States of America.

View Article and Find Full Text PDF
February 2013

The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2.

J Lipid Res 2012 Jun 3;53(6):1106-16. Epub 2012 Apr 3.

Cardiovascular and Metabolic Disease Research and Community of Research Excellence and Advanced Technology, Janssen Pharmaceutical Companies of Johnson and Johnson, Spring House, PA 19477, USA.

View Article and Find Full Text PDF
June 2012

Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.

Bioorg Med Chem Lett 2010 Feb 4;20(4):1432-5. Epub 2010 Jan 4.

Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh & McKean Roads, PO Box 776, Spring House, PA 19477-0776, USA.

View Article and Find Full Text PDF
February 2010

Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.

Bioorg Med Chem Lett 2009 May 18;19(9):2456-60. Epub 2009 Mar 18.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Metabolic Disorders Team, 1000 Route 202, P.O. Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
May 2009

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

Eur J Pharmacol 2008 Aug 7;590(1-3):333-42. Epub 2008 Jun 7.

Johnson & Johnson Pharmaceutical Research & Development, Welsh and McKean Roads, Spring House, PA 19477-0776, USA.

View Article and Find Full Text PDF
August 2008

Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

Bioorg Med Chem Lett 2007 Dec 17;17(24):6773-8. Epub 2007 Oct 17.

Drug Discovery, Johnson & Johnson, East Coast RED, Spring House, PA 19477-0776, USA.

View Article and Find Full Text PDF
December 2007

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

J Med Chem 2007 Jun 15;50(12):2807-17. Epub 2007 May 15.

Drug Discovery Division, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., 8 Clarke Drive, Cranbury, New Jersey 08512, USA.

View Article and Find Full Text PDF
June 2007

Human epidermoid A431 cells express functional nicotinic acid receptor HM74a.

Mol Cell Biochem 2007 Jan 24;294(1-2):243-8. Epub 2006 Nov 24.

Endocrine Therapeutics and Metabolic Disorders Team, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
January 2007

Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A.

Biochem Biophys Res Commun 2006 Jun 25;345(1):29-37. Epub 2006 Apr 25.

Endocrine Therapeutics and Metabolic Disorders, The Johnson and Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
June 2006

Synthesis and SAR of 1,3-disubstituted cyclohexylmethyl urea and amide derivatives as non-peptidic motilin receptor antagonists.

Bioorg Med Chem Lett 2006 Jul 2;16(13):3362-6. Epub 2006 May 2.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
July 2006

Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.

Bioorg Med Chem Lett 2006 Mar 27;16(6):1696-701. Epub 2005 Dec 27.

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
March 2006

Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.

Bioorg Med Chem Lett 2005 Dec 28;15(23):5202-6. Epub 2005 Sep 28.

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
December 2005

Distinctive and synergistic signaling of human adenosine A2a and dopamine D2L receptors in CHO cells.

J Recept Signal Transduct Res 2005 ;25(3):159-79

Endocrine Therapeutics and Metabolic Disorders, The Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
November 2005

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors.

Bioorg Med Chem Lett 2005 Nov;15(21):4790-3

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
November 2005

Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.

Br J Pharmacol 2005 Nov;146(5):654-61

Unitat de Cèl.lules Troncals, Hospital Clínic Univesitari, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Instituto Reina Sofía de Investigaciones Nefrológicas, Barcelona, Spain.

View Article and Find Full Text PDF
November 2005

Nuclear receptors as potential targets for modulating reverse cholesterol transport.

Curr Top Med Chem 2005 ;5(3):265-82

Department of Drug Discovery, Endocrine Therapeutics and Metabolic Diseases, Johnson & Johnson Pharmaceutical Research and Development, LLC., 1000 Route 202, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
June 2005

Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats.

Am J Physiol Endocrinol Metab 2005 Mar 9;288(3):E617-24. Epub 2004 Nov 9.

Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, USA.

View Article and Find Full Text PDF
March 2005

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors.

Bioorg Med Chem Lett 2004 Oct;14(20):5121-5

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
October 2004

Development of a sensitive and HTS-compatible reporter gene assay for functional analysis of human adenosine A2a receptors in CHO-K1 cells.

Assay Drug Dev Technol 2004 Jun;2(3):281-9

Department of Drug Discovery, Endocrine Therapeutics and Metabolic Disorders, The Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
June 2004

Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.

Bioorg Med Chem Lett 2004 Jun;14(12):3143-6

Endocrine Therapeutics and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Bldg: PCC, Room: PC110, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
June 2004

Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.

Bioorg Med Chem Lett 2004 Jun;14(11):2987-9

Endocrine Therapeutics and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, L.L.C. 1000 Route 202, Bldg: PCC; Room: PC110, Raritan, NJ 08869-0602, USA.

View Article and Find Full Text PDF
June 2004

Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.

Diabetes 2004 Feb;53(2):410-7

Endocrine Therapeutic and Metabolic Disorders, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey, USA.

View Article and Find Full Text PDF
February 2004

2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.

Bioorg Med Chem Lett 2003 Nov;13(22):4031-4

Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, Raritan, NJ 08869-0602, USA.

View Article and Find Full Text PDF
November 2003

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1).

J Cell Biochem 2003 Oct;90(2):339-46

Endocrine Therapeutics and Metabolic Disorders Team, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, LLC., Raritan, New Jersey 08869, USA.

View Article and Find Full Text PDF
October 2003

Benzoxazinones as PPARgamma agonists. part 1: SAR of three aromatic regions.

Bioorg Med Chem Lett 2003 Jul;13(14):2359-62

Johnson and Johnson Pharmaceutical Research and Development, LLC, 08869, Raritan, NJ, USA.

View Article and Find Full Text PDF
July 2003

The use of biosensors to study GPCR function: applications for high-content screening.

Recept Channels 2002 ;8(5-6):331-41

Department of Drug Discovery, R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey, USA.

View Article and Find Full Text PDF
June 2003